Abstract
Iron chelation has been a life saving therapy for thalassaemia major patients over the past 30 years. With the introduction of orally active chelators, other diseases are now also being treated, for instance sickle cell disease, myeloma dysplasia and Friedreich ataxia. Indeed, iron chelators are showing potential for the retardation of various neurodegenerative disorders. This presentation will provide an update on the progress of such studies.
| Original language | English |
|---|---|
| Pages (from-to) | 1369 - 1370 |
| Number of pages | 2 |
| Journal | Journal of Pharmacy and Pharmacology |
| Volume | 62 |
| Issue number | 10 |
| Publication status | Published - 2010 |